Chancroid is a sexually transmitted infection caused by the bacterium Haemophilus ducreyi. Our company is committed to providing one-stop solutions to global pharmaceutical companies with its expertise in chancroid vaccine and therapy development.
Overview of Chancroid
Chancroid, also known as soft chancre, is a highly contagious sexually transmitted infection characterized by painful genital ulcers. Primarily affecting the genital region, chancroid is caused by the Gram-negative bacterium Haemophilus ducreyi. This pathogen primarily targets the mucous membranes, leading to the formation of painful ulcers and subsequent lymph node swelling in the affected individuals.
Fig. 1 Example of gram stain analysis in chancroid. (Putri P.T.A.D., et al., 2021)
Vaccine Development for Chancroid
Vaccination has proven to be an effective strategy in preventing and controlling infectious diseases. Chancroid vaccine development aims to stimulate the immune system to recognize and neutralize Haemophilus ducreyi, ultimately preventing chancroid infection.
Reverse vaccinology involves the systematic analysis of the pathogen's genome and proteome to identify potential vaccine targets. By leveraging bioinformatics tools and computational algorithms, researchers can identify conserved antigens and epitopes that have the potential to elicit a robust immune response.
Therapeutics Development for Chancroid
Currently, antibiotic therapy is the mainstay for treating chancroid. The choice of antibiotic depends on the susceptibility patterns of the local strains of H. ducreyi. Recommended antibiotics include ceftriaxone, azithromycin, and erythromycin. However, the emergence of antibiotic resistance poses a significant challenge in the effective management of chancroid. Therefore, our focus extends beyond conventional antibiotics, as we explore innovative approaches such as targeted therapies and immunomodulatory agents to enhance outcomes. Please click on the link below to learn more about our one-stop solutions.
Our Services
At our company, we pride ourselves on providing a comprehensive array of services in the development of vaccines and therapies targeting chancroid. With a team of exceptionally talented researchers and scientists, we are fully committed to pushing the boundaries of scientific knowledge and spearheading advancements in the battle against chancroid.
- Swine Model of Haemophilus ducreyi Infection
- Mouse Model of Haemophilus ducreyi Infection
- Macaca Nemestrina Model of Haemophilus ducreyi Infection
Through our unwavering dedication and utilization of state-of-the-art research methodologies, we strive to deliver innovative solutions that have the potential to transform the landscape of chancroid therapeutics. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and obtain a detailed quotation for the services you require.
References
- Putri, Raja Tina Anggrainy Dwi, et al. "Chancroid Coexisting with Vaginal Candidiasis: A Case Report." Open Access Macedonian Journal of Medical Sciences 9.C (2021): 318-321.
- Fadnavis, Shreya, et al. "Chancroid vaccine: Solving the puzzle within a proteome of Haemophilus ducreyi to reach the target vaccine leads by reverse vaccinology approach." Journal of Pharmacy Research 12.4 (2018): 636.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
